Recist Calculator

Use this RECIST Calculator to assess tumor response based on RECIST 1.1 criteria by entering baseline and follow-up measurements of target lesions.

Target Lesion Measurements (mm)

Lesion	Baseline (mm)	Follow-up (mm)
1
2
3
4
5

Table 1: Baseline and Follow-up Lesion Measurements

Figure 1: Baseline vs Follow-up Sum of Longest Diameters (SLD)

What is a RECIST Calculator?

A RECIST Calculator is a tool used primarily in oncology to evaluate the response of solid tumors to treatment based on the “Response Evaluation Criteria in Solid Tumors” (RECIST) guidelines, specifically version 1.1. It standardizes how tumor size changes are measured and categorized over time, usually through imaging techniques like CT or MRI scans. The RECIST Calculator helps clinicians and researchers determine if a patient’s cancer is shrinking (responding), growing (progressing), or remaining stable during or after therapy.

This calculator is used by oncologists, radiologists, and researchers involved in clinical trials and cancer patient care. It helps in assessing the efficacy of cancer treatments by providing objective criteria for response. Common misconceptions include thinking RECIST applies to all cancer types (it’s mainly for solid tumors with measurable lesions) or that it’s the only measure of treatment success (patient symptoms and quality of life are also crucial).

RECIST Calculator Formula and Mathematical Explanation

The RECIST Calculator relies on measuring the longest diameter (LD) of “target lesions” (selected measurable tumors) at baseline and follow-up time points.

1. Baseline Sum of Longest Diameters (SLD): The sum of the LDs of all target lesions before or at the start of treatment.
   
   Baseline SLD = LD₁ + LD₂ + … + LD_n
2. Follow-up Sum of Longest Diameters (SLD): The sum of the LDs of the same target lesions at a follow-up assessment.
   
   Follow-up SLD = LD’₁ + LD’₂ + … + LD’_n
3. Percentage Change: The change in SLD from baseline to follow-up, expressed as a percentage.
   
   % Change = ((Follow-up SLD – Baseline SLD) / Baseline SLD) * 100
4. Response Categorization (Simplified):
   • Complete Response (CR): Disappearance of all target lesions (Follow-up SLD = 0), no new lesions, no progression of non-target lesions.
   • Partial Response (PR): ≥ 30% decrease in SLD from baseline, no new lesions, no progression of non-target lesions.
   • Progressive Disease (PD): ≥ 20% increase in SLD from baseline (and ≥ 5mm absolute increase), OR appearance of new lesions, OR unequivocal progression of non-target lesions. For PD, the reference is usually the smallest SLD recorded (nadir), but our calculator uses baseline as a primary reference for simplicity before considering new/non-target issues.
   • Stable Disease (SD): Insufficient decrease for PR and insufficient increase for PD, no new lesions, no progression of non-target lesions.

Variables Table:

Variable	Meaning	Unit	Typical Range
LDi	Longest diameter of lesion ‘i’ at baseline	mm	5 – 200+
LD’i	Longest diameter of lesion ‘i’ at follow-up	mm	0 – 200+
Baseline SLD	Sum of LDs at baseline	mm	10 – 500+
Follow-up SLD	Sum of LDs at follow-up	mm	0 – 500+

Practical Examples (Real-World Use Cases)

Example 1: Partial Response

A patient with lung cancer has two target lesions measured at baseline: Lesion 1 = 40mm, Lesion 2 = 30mm. Baseline SLD = 40 + 30 = 70mm.

After treatment, at follow-up: Lesion 1 = 20mm, Lesion 2 = 15mm. Follow-up SLD = 20 + 15 = 35mm. No new lesions or non-target progression reported.

Percentage Change = ((35 – 70) / 70) * 100 = -50%.

Since the decrease is >30% and there are no signs of progression, the response is Partial Response (PR) according to the RECIST Calculator.

Example 2: Progressive Disease

A patient with colon cancer has one target lesion: Baseline Lesion 1 = 25mm. Baseline SLD = 25mm.

At follow-up: Lesion 1 = 35mm. Follow-up SLD = 35mm. Additionally, a new lesion is identified.

Percentage Change = ((35 – 25) / 25) * 100 = +40%. The absolute increase is 10mm.

Even though the percentage increase is >20% (and absolute >5mm), the presence of a new lesion automatically qualifies this as Progressive Disease (PD) using the RECIST Calculator.

How to Use This RECIST Calculator

1. Enter Baseline Measurements: Input the longest diameter (in mm) for each identified target lesion (up to 5) before treatment or at the start. If fewer than 5 lesions, leave the extra fields blank or enter 0.
2. Enter Follow-up Measurements: Input the longest diameter (in mm) for the same target lesions at the follow-up time point. Enter 0 if a lesion has disappeared.
3. Indicate New Lesions: Select “Yes” or “No” if any new lesions were detected at follow-up.
4. Indicate Non-Target Progression: Select “Yes” or “No” if there was unequivocal progression of non-target lesions.
5. View Results: The RECIST Calculator will automatically display the Baseline SLD, Follow-up SLD, Percentage Change, and the overall RECIST Response (CR, PR, SD, or PD). The table and chart will also update.
6. Interpret: CR and PR generally indicate a positive response to treatment. SD means the disease is controlled but not significantly shrinking. PD indicates the treatment may not be effective. Always consult with an oncologist for clinical interpretation. See our RECIST 1.1 guidelines for more details.

Key Factors That Affect RECIST Calculator Results

• Measurement Accuracy: Precise measurement of the longest diameter by the radiologist is critical. Inter-observer variability can affect results. Learn more about how to measure tumors.
• Lesion Selection: The choice of target lesions at baseline influences the SLD and subsequent response assessment. Only measurable lesions (typically ≥10mm, or ≥15mm short axis for lymph nodes) should be target lesions.
• Imaging Modality and Technique: Consistency in using the same imaging modality (e.g., CT, MRI) and technique across time points is important for comparable measurements.
• Timing of Assessments: Follow-up scans are done at predefined intervals. The timing can influence the observed change.
• Presence of New Lesions: The appearance of even one new lesion generally signifies progressive disease, regardless of changes in target lesions.
• Non-Target Lesion Progression: Unequivocal progression of non-target lesions (those not selected as target lesions) also indicates progressive disease.
• Definition of “Unequivocal Progression”: This can sometimes be subjective for non-target lesions or new lesions and requires careful radiological interpretation.
• Cavitary or Cystic Lesions: Measuring these can be challenging and may require specific considerations.

Frequently Asked Questions (FAQ)

What does RECIST stand for?

Response Evaluation Criteria in Solid Tumors.

What is the minimum size for a measurable target lesion in RECIST 1.1?

Generally, ≥10 mm in longest diameter (or ≥15 mm in short axis for lymph nodes), measurable by CT or MRI with a slice thickness of ≤5 mm.

How many target lesions are typically selected?

Up to a maximum of 5 target lesions in total, and a maximum of 2 per organ, are selected at baseline and followed throughout the study/treatment.

What if a target lesion disappears?

If a target lesion is no longer visible or measurable, its diameter at follow-up is recorded as 0 mm for the SLD calculation by the RECIST Calculator.

Can RECIST be used for non-solid tumors like leukemia?

No, RECIST is designed for solid tumors. Hematological malignancies have different response criteria.

What is “nadir” in RECIST?

Nadir refers to the smallest Sum of Longest Diameters (SLD) recorded since the start of treatment. Progressive Disease (PD) based on target lesion increase is defined relative to the nadir SLD.

Does the RECIST Calculator account for nadir?

This simplified RECIST Calculator primarily compares follow-up to baseline for PR/PD percentage changes but flags PD if new lesions or non-target progression occur. For strict PD based on size increase from nadir, the nadir value would need to be tracked separately.

What if I have more than 5 target lesions?

RECIST 1.1 guidelines recommend selecting up to 5 representative target lesions. The remaining are considered non-target lesions.

Related Tools and Internal Resources

• RECIST 1.1 Guidelines Explained: A detailed look at the official RECIST 1.1 criteria for tumor response evaluation.
• How to Measure Tumors for RECIST: Best practices for radiological measurement of lesions.
• Understanding Cancer Staging: Learn about how cancers are staged and classified.
• Clinical Trial Design in Oncology: Information on how studies evaluating cancer treatments are structured, where the RECIST Calculator is often used.
• Oncology Resources: A collection of resources for patients and professionals.
• Imaging Techniques in Cancer: An overview of CT, MRI, and PET scans used in oncology.